GARS1 and urothelial carcinoma: Chen et al. used iTRAQ proteomics technology in samples from urothelial carcinoma and chronic kidney disease patients and found that GARS was more highly expressed in urothelial carcinoma and could be used as a diagnostic marker for urothelial carcinoma [40].